Willow Neuroscience, Inc. | 10 followers on LinkedIn. Willow Biosciences is a Stanford-founded company reversing aging at its source. Our lead programs are an IDO1 inhibitor for early Alzheimer’s — near human trials and shown in preclinical models to reverse dementia-like symptoms by restoring brain energy supply — and TREM1-PET, a first-in-class companion diagnostic already in clinical trials to track both TREM1 and EP2 activation. TREM1-PET guides patient selection and treatment monitoring to increase trial success rates and will directly inform the highest-value disease indications for our pipeline.